Tacoma, Colorado Springs and Salt Lake City Have the Highest Percentage of HIV Patients in the U.S. Who Are Left Untreated

NASHVILLE, Tenn., Sept. 16 /PRNewswire/ -- HealthLeaders-InterStudy, a leading provider of managed care market intelligence, estimates that Tacoma, WA; Colorado Springs, CO and Salt Lake City, UT have the highest percentage of HIV patients who are left untreated. PatientFinder, HealthLeaders-InterStudy's analytics tool, finds that in these areas, 79 percent, 74 percent and 77 percent, respectively, of HIV positive individuals are not receiving any treatment and have prescription drug insurance.

"The high percentage of untreated patients who have prescription drug insurance in these markets is a great opportunity for pharmaceutical companies wishing to grow their patient base," says Andrew Laubscher, product director, PatientFinder. "Their focus should be on small- and mid-size markets to most effectively drive volume growth among patients who are not receiving treatment."

In addition, there are still an additional nine markets in the United States that have treatment rates below 20%, according to PatientFinder. While there are seven major U.S. markets with HIV treatment rates above 90%, there is a high variation in treatment rates across the U.S. that leave a significant amount of HIV patients untreated.

About PatientFinder

PatientFinder covers each of the 50 U.S. states and U.S. metropolitan statistical areas (MSAs) and provides:

• Disease-specific prevalence numbers for each U.S. state and MSA.
• Examination of treatment rates for the disease population to create percent treated and percent untreated estimates by state and MSA.
• Unique analysis of the untreated population examined through a filter of pharmacy benefit coverage. The end result is an estimate of how many patients are untreated but can afford therapy within each territory -- the true local measure of opportunity for pharmaceutical companies.

Indications covered in 2010 to include*:

• Alzheimer's disease
• Asthma
• Bipolar depression
• Chronic obstructive pulmonary disease
• Crohn's disease
• Dyslipidemia
• Hepatitis C virus
• HIV
• Hypertension
• Major depression
• Multiple sclerosis
• Parkinson's disease
• Psoriasis
• Rheumatoid arthritis
• Schizophrenia
• Type 2 diabetes (non-insulin)
• Ulcerative colitis

*Indications subject to change.

Why Pharmaceutical Companies Need This Information

With the type of information included in PatientFinder, pharmaceutical organizations can identify the local markets that offer the greatest opportunity for their branded drug. Companies can identify markets that are underserved and determine if they should increase direct-to-consumer advertising, work with the local managed care organizations to increase awareness of the disease and benefits of their drug or align sales representatives to maximize market potential.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE HealthLeaders-InterStudy

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED